Intelligence · Clinical Pipeline
Kailera Therapeutics Pipeline
All ClinicalTrials.gov programs at Kailera Therapeutics — phase, modality, and trial IDs.
- Programs
- 7
Quick answer
Kailera Therapeutics has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Drug GC4711
Galera Therapeutics
SBRT
1 trial -
Drug: GC4419
Galera Therapeutics
Head and Neck Cancer
1 trial -
GC4419
Galera Therapeutics
Covid19
1 trial -
GC4419
Galera Therapeutics
Pancreatic Cancer
1 trial -
GC4419 (avasopasem manganese)
Galera Therapeutics
Esophagitis
1 trial -
GC4711 +SBRT
Galera Therapeutics
SBRT
1 trial -
Low Dose GC4419: 30mg/day
Galera Therapeutics
Radiation Induced Oral Mucositis
1 trial
Frequently asked questions
How many pipeline programs does Kailera Therapeutics have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs